GLP-1 Market
LLY $1415.87 ▲ +0.3% NVO $40.42 ▼ -2.3% PFE $29.07 ▼ -0.5% VKTX $29.19 ▲ +0.7% KLRA $13.80 ▲ +0.8% GPCR $21.25 ▼ -0.7% RHHBY $61.32 ▲ +3.3%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

KAI-4729

KAI-4729

Company
Kailera
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
None currently listed

Efficacy results: Not yet reported

No recruiting studies currently listed

See all studies for this drug

Data source: ClinicalTrials.gov · trial data as of Nov 10, 2026

Trial details
  • Not yet recruiting NCT NCT07924761

    A Study to Investigate the Effect of Injection Site and Ethnicity on KAI-4729 Pharmacokinetics in Non-Asian and Asian Participants Living With Obesity or Overweight

    Not yet reported Kailera 60 participants Est. completion 2027-04 1 site Stand-alone
    Other conditions: Overweight or Obesity
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources
Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.